Allopurinol Versus Simvastatin to Prevent Complications of Liver Cirrhosis

• Status: Not yet recruiting
• Trial end date: 2025-01-30
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to compare the potential benefit of allopurinol versus simvastatin in reducing the risk of developing cirrhosis-related complications, delaying the onset of hepatocellular carcinoma, and improving survival. Furthermore, the study aims to evaluate their impact on parents' related quality of life.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Allopurinol; Simvastatin

Criteria

Inclusion Criteria:

• Inclusion Criteria

• Age 18 to 75 years old

• Both sex

• Adults with cirrhosis in a stable conditions

Exclusion Criteria:

• Exclusion criteria

• Active SBP

• Renal insufficiency (serum creatinine > 2.0 mg/dl)

• Active GIT hemorrhage